Zila goes to Tolmar
This article was originally published in The Gray Sheet
Executive Summary
Maker of the ViziLite Plus screening product for the early detection of oral abnormalities that could lead to cancer is acquired by dental pharmaceutical firm Tolmar Holding for $4 million in cash, plus the assumption of $12 million in Zila debt, the firm announces June 25. "We are fortunate to have entered into this merger agreement with Tolmar, given Zila's current financial condition and our inability to access the financial markets," said Zila CEO David Bethune. Tolmar will pay $0.38 for each of Zila's 10.4 million shares outstanding, an 18% premium over the June 24 close of $0.32
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.